FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308806189> ?p ?o ?g. }

• W4308806189 endingPage "1582" @default.
• W4308806189 startingPage "1576" @default.
• W4308806189 abstract "We sought to describe clinicopathologic and treatment factors associated with oncologic outcomes in patients with early-stage ovarian clear cell carcinoma undergoing complete staging and in a sub-set of these patients undergoing fertility-conserving surgery.We retrospectively identified patients with ovarian clear cell carcinoma initially treated at our institution from January 1, 1996 to March 31, 2020. Survival was estimated using Kaplan-Meier curves and compared by log-rank test. Survival-associated variables were identified by Cox proportional hazards regression.Of 182 patients, mismatch repair and p53 protein expression were assessed by immunohistochemistry on 82 and 66 samples, respectively. There were no significant differences in progression-free survival or overall survival between mismatch repair-deficient (n=6, including 4 patients with Lynch syndrome; 7.3%) and mismatch repair-proficient patients, whereas aberrant p53 expression (n=3; 4.5%) was associated with worse progression-free (p<0.001) and overall survival (p=0.01). Patients with stage IA/IC1 disease had a 95% 5-year overall survival rate (95% CI 88% to 98%); patients with stage IC2/IC3 disease had a similar 5-year overall survival rate (76%; 95% CI 54% to 88%) to that of patients with stage IIA/IIB disease (82%; 95% CI 54% to 94%). There was no difference in 5-year overall survival in patients with stage IA/IC1 undergoing chemotherapy versus observation (94% vs 100%). Nine patients underwent fertility-sparing surgery and none experienced recurrence. Of five patients who pursued fertility, all had successful pregnancies.In patients with completely staged ovarian clear cell carcinoma, those with stage IA/IC1 disease have an excellent prognosis, regardless of chemotherapy. Aberrant p53 expression may portend worse outcomes. Additional investigation is warranted on the safety of fertility conservation in patients with stage IA/IC1 disease." @default.
• W4308806189 created "2022-11-15" @default.
• W4308806189 creator A5001429608 @default.
• W4308806189 creator A5002011120 @default.
• W4308806189 creator A5010580155 @default.
• W4308806189 creator A5017569198 @default.
• W4308806189 creator A5023685848 @default.
• W4308806189 creator A5025321281 @default.
• W4308806189 creator A5029189660 @default.
• W4308806189 creator A5029200876 @default.
• W4308806189 creator A5040490427 @default.
• W4308806189 creator A5040506127 @default.
• W4308806189 creator A5046393441 @default.
• W4308806189 creator A5046956876 @default.
• W4308806189 creator A5048186556 @default.
• W4308806189 creator A5054602117 @default.
• W4308806189 creator A5062656089 @default.
• W4308806189 creator A5075806320 @default.
• W4308806189 creator A5083345435 @default.
• W4308806189 date "2022-11-11" @default.
• W4308806189 modified "2023-09-27" @default.
• W4308806189 title "Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation" @default.
• W4308806189 cites W1968744509 @default.
• W4308806189 cites W1979879868 @default.
• W4308806189 cites W2026955611 @default.
• W4308806189 cites W2031006833 @default.
• W4308806189 cites W2079671397 @default.
• W4308806189 cites W2120079339 @default.
• W4308806189 cites W2125681453 @default.
• W4308806189 cites W2130941707 @default.
• W4308806189 cites W2154175915 @default.
• W4308806189 cites W2154885792 @default.
• W4308806189 cites W2314787270 @default.
• W4308806189 cites W2328024626 @default.
• W4308806189 cites W2568525023 @default.
• W4308806189 cites W2754235234 @default.
• W4308806189 cites W2943306812 @default.
• W4308806189 cites W2979653833 @default.
• W4308806189 cites W3001395372 @default.
• W4308806189 cites W3081084917 @default.
• W4308806189 cites W3087700560 @default.
• W4308806189 cites W4239330499 @default.
• W4308806189 cites W4294982904 @default.
• W4308806189 cites W63206568 @default.
• W4308806189 doi "https://doi.org/10.1136/ijgc-2022-003935" @default.
• W4308806189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36368707" @default.
• W4308806189 hasPublicationYear "2022" @default.
• W4308806189 type Work @default.
• W4308806189 citedByCount "0" @default.
• W4308806189 crossrefType "journal-article" @default.
• W4308806189 hasAuthorship W4308806189A5001429608 @default.
• W4308806189 hasAuthorship W4308806189A5002011120 @default.
• W4308806189 hasAuthorship W4308806189A5010580155 @default.
• W4308806189 hasAuthorship W4308806189A5017569198 @default.
• W4308806189 hasAuthorship W4308806189A5023685848 @default.
• W4308806189 hasAuthorship W4308806189A5025321281 @default.
• W4308806189 hasAuthorship W4308806189A5029189660 @default.
• W4308806189 hasAuthorship W4308806189A5029200876 @default.
• W4308806189 hasAuthorship W4308806189A5040490427 @default.
• W4308806189 hasAuthorship W4308806189A5040506127 @default.
• W4308806189 hasAuthorship W4308806189A5046393441 @default.
• W4308806189 hasAuthorship W4308806189A5046956876 @default.
• W4308806189 hasAuthorship W4308806189A5048186556 @default.
• W4308806189 hasAuthorship W4308806189A5054602117 @default.
• W4308806189 hasAuthorship W4308806189A5062656089 @default.
• W4308806189 hasAuthorship W4308806189A5075806320 @default.
• W4308806189 hasAuthorship W4308806189A5083345435 @default.
• W4308806189 hasBestOaLocation W43088061891 @default.
• W4308806189 hasConcept C10515644 @default.
• W4308806189 hasConcept C121608353 @default.
• W4308806189 hasConcept C126322002 @default.
• W4308806189 hasConcept C143998085 @default.
• W4308806189 hasConcept C146357865 @default.
• W4308806189 hasConcept C151730666 @default.
• W4308806189 hasConcept C2777546739 @default.
• W4308806189 hasConcept C2780427987 @default.
• W4308806189 hasConcept C2908647359 @default.
• W4308806189 hasConcept C29456083 @default.
• W4308806189 hasConcept C50382708 @default.
• W4308806189 hasConcept C518429986 @default.
• W4308806189 hasConcept C71924100 @default.
• W4308806189 hasConcept C86803240 @default.
• W4308806189 hasConcept C99454951 @default.
• W4308806189 hasConceptScore W4308806189C10515644 @default.
• W4308806189 hasConceptScore W4308806189C121608353 @default.
• W4308806189 hasConceptScore W4308806189C126322002 @default.
• W4308806189 hasConceptScore W4308806189C143998085 @default.
• W4308806189 hasConceptScore W4308806189C146357865 @default.
• W4308806189 hasConceptScore W4308806189C151730666 @default.
• W4308806189 hasConceptScore W4308806189C2777546739 @default.
• W4308806189 hasConceptScore W4308806189C2780427987 @default.
• W4308806189 hasConceptScore W4308806189C2908647359 @default.
• W4308806189 hasConceptScore W4308806189C29456083 @default.
• W4308806189 hasConceptScore W4308806189C50382708 @default.
• W4308806189 hasConceptScore W4308806189C518429986 @default.
• W4308806189 hasConceptScore W4308806189C71924100 @default.
• W4308806189 hasConceptScore W4308806189C86803240 @default.
• W4308806189 hasConceptScore W4308806189C99454951 @default.

• next